Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Try a single issue or save on a subscription Issues delivered straight to your door or device ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

When most people think about sleep apnea, I’d assume they think of snoring. Snoring is just one type of sleep apnea that most ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA ... a reduction to mild OSA, compared ...

The Food and Drug Administration (FDA) gave the green light to the the first-ever medication for obstructive sleep apnea (OSA ... obesity suffering from moderate to severe OSA.

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA ... remission or mild nonsymptomatic OSA compared ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea ... Zepbound were mild to moderate ...

The Epidemiological Study of Sleep ("Episono") has been ... Between five and 15 is classed as mild apnea, 15-30 is moderate, and more than 30 is severe," Cavalcante-Silva says.